Thank you for subscribing!
Learn More about Next Investors - Experts in Biotech Stocks
Next Investors Archived Jul 10, 2018
Leading medical device company Neurotech International (ASX:NTI) this week reported highly promising results from US clinical trials of its Mente autism device.
Next Investors Archived Jun 26, 2018
Today’s company has created the first and only regulated medical device for the management of autism in a home setting.
Next Investors Archived Jun 07, 2018
Immuron Limited (ASX:IMC | NASDAQ:IMRN) is focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.
Next Investors Archived May 21, 2018
BARD1 Life Sciences Limited (ASX:BD1) has both lung and ovarian cancer in its sights.
Get expert stock analysis direct in your inbox
Next Investors Archived May 17, 2018
Prescient Therapeutics (ASX:PTX) is looking to prove up its two breast cancer therapies, putting it ahead of the field in areas of high unmet need.
Next Investors Archived May 16, 2018
Creso Pharma (ASX:CPH) has today informed the market that it has entered into a joint venture with Cohen Propagation Nurseries Limited to operate a high quality medicinal cannabis growing facility in Israel.
Next Investors Archived Apr 12, 2018
MGC Pharmaceuticals (ASX:MXC) has wasted no time ramping up its game in 2018.
Next Investors Archived Mar 13, 2018
This biotech appears to have cracked one of the holy grails of cancer research: it’s currently in human clinical trials with not one, but two innovative drugs which ‘turn off the switch’ that would otherwise allow cancerous cells to grow via the important Akt and Ras pathways.
Next Investors Archived Mar 08, 2018
Australian microbiome biopharmaceutical company, Immuron Limited (ASX:IMC | NASDAQ:IMRN) continues to progress its oral immunotherapies, to supply solutions for a growing unmet need.
Join Our Mailing List
